CEL-SCI Corporation
502 articles about CEL-SCI Corporation
-
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
7/11/2023
CEL-SCI Corporation (NYSE American: CVM) today announced new data from a biomarker analysis of its pivotal Phase 3 study in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN) at the American Head and Neck Cancer Society’s (AHNS) 11th Annual International Conference.
-
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
6/22/2023
CEL-SCI Corporation announced it will present the new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck, at the American Head and Neck Cancer Society’s 11th Annual International Conference on Head and Neck Cancer on July 8-12, 2023 in Montreal, Canada.
-
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
5/15/2023
CEL-SCI Corporation announced that the latest results from its pivotal Phase 3 study of Multikine were presented at the ESTRO 2023 Congress in Vienna, Austria in a poster presentation titled “Histopathology population confirms Multikine* [Leukocyte Interleukin Injection ] treatment outcome in naïve locally advanced primary head & neck squamous cell carcinoma SCCHN)” during the Head & Neck Cancer Session on Saturday, May 13, 2023.
-
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
5/12/2023
CEL-SCI Corporation reported financial results for the quarter ended March 31, 2023, as well as key clinical and corporate developments.
-
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
4/28/2023
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.
-
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
4/19/2023
CEL-SCI Corporation (NYSE American: CVM) today announced it has held a productive pre-submission meeting with Canada’s regulator to determine the best regulatory path toward market approval.
-
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
3/8/2023
CEL-SCI Corporation (NYSE American: CVM) today reported new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
-
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
3/3/2023
CEL-SCI Corporation (NYSE American: CVM) today announced it will present new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN), on March 8, 2023 at the 10th European Congress on Head & Neck Oncology in Lisbon, Portugal.
-
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
2/15/2023
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.
-
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
12/28/2022
CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments.
-
CEL-SCI Corporation Issues Letter to Shareholders - November 22, 2022
11/22/2022
CEL-SCI Corporation issued a letter to its shareholders. Dear CEL-SCI Shareholders: I wanted to write to update you on our progress.
-
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
10/17/2022
CEL-SCI Corporation (NYSE American: CVM) today announced the availability to the public of an oral presentation delivered by Dr. Philip Lavin of groundbreaking tumor response and increased overall survival in head and neck cancer.
-
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
9/12/2022
CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) annual Congress on September 10, 2022 in Paris, France.
-
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
8/19/2022
CEL-SCI Corporation Announces Phase 3 Multikine ® Head and Neck Cancer Results Posted on Clinicaltrials.gov.
-
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
8/15/2022
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2022, as well as key clinical and corporate developments.
-
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
8/8/2022
CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors.
-
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
7/14/2022
CEL-SCI Corporation (NYSE American: CVM) announces that Geert Kersten, Chief Executive Officer, will be on Reddit AMA (“Ask Me Anything”) today at 12:30 PM ET to discuss Multikine and our recent publications at ASCO 2022.
-
CEL-SCI Corporation to Present at LD Micro Invitational
6/8/2022
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro Invitational XII Conference today, June 8, 2022 at 4:30 p.m. EDT.
-
CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.
-
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
6/7/2022
CEL-SCI Corporation (NYSE American: CVM) today announced that its abstract and poster titled “Leukocyte interleukin injection (LI) immunotherapy extends overall survival (OS) in treatment-naive low-risk (LR) locally advanced primary squamous cell carcinoma of the head and neck.